Overview

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Status:
RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Spanish Oncology Genito-Urinary Group

Collaborators:

Janssen-Cilag Ltd.
Pivotal S.L.